GPhA: FDA should revise draft guidelines on biosimilar meetings

06/5/2013 | Bloomberg BNA (free content)

Some revisions are needed for the draft guidance on formal meetings between the FDA and sponsors of biosimilar products, the Generic Pharmaceutical Association said. "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants" must be clarified to guarantee a full understanding of the requirements and expectations of the FDA, the group said. It added the FDA should explain if a request for a first biosimilar advisory meeting can be rejected and give guidance on such situations.

View Full Article in:

Bloomberg BNA (free content)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD